Overview
N-GAL Allows Intensive Treatment of Contrast Induced Nephropathy
Status:
Unknown status
Unknown status
Trial end date:
2017-12-01
2017-12-01
Target enrollment:
0
0
Participant gender:
All
All
Summary
Patients who undergo urgent/emergency coronary angiography can not receive any preventive treatment of contrast induced nephropathy. We tested the hypothesis that Neutrophil gelatinase-associated lipocalin (NGAL), a new biomarker predictive for AKI, allows early and effective treatment of contrast induced nephropathy in patients with urgent/emergency coronary angiographyPhase:
Phase 4Accepts Healthy Volunteers?
NoDetails
Lead Sponsor:
University of Roma La Sapienza
Criteria
Inclusion Criteria:- Indication to urgent/emergency coronary angiography
- Normal renal function (eGFR> 60 ml/min/1.73 m2)
- Moderate or high Mehran's risk score for CIN (>11).
- Able to understand and willing to sign the informed consent form
Exclusion Criteria:
• Women of child bearing potential patients must demonstrate a negative pregnancy test
performed within 24 hours before